TY - JOUR
T1 - BTK inhibitor selection for chronic lymphocytic leukemia
T2 - which drug for which patient?
AU - Desikan, Sai Prasad
AU - Venugopal, Sangeetha
AU - Ferrajoli, Alessandra
N1 - Funding Information:
A Ferrajoli has received research funding from BeiGene and Astrazeneca. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: The development of BTK inhibitors has revolutionized the management of CLL. Currently, there are 3 BTK inhibitors available to treat CLL: ibrutinib, acalabrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN guidelines). In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy. Areas covered: This review utilizes data from published prospective trials, specifically RESONATE, RESONATE-2, ELEVATE-TN, ASCEND, ELEVATE-RR, and the ongoing FLAIR, SEQUOIA, and ALPINE trials. Expert opinion: The choice of BTK inhibitor is guided by the setting (frontline vs relapsed) in conjunction with patient disease characteristics and comorbidities. In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy.
AB - Introduction: The development of BTK inhibitors has revolutionized the management of CLL. Currently, there are 3 BTK inhibitors available to treat CLL: ibrutinib, acalabrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN guidelines). In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy. Areas covered: This review utilizes data from published prospective trials, specifically RESONATE, RESONATE-2, ELEVATE-TN, ASCEND, ELEVATE-RR, and the ongoing FLAIR, SEQUOIA, and ALPINE trials. Expert opinion: The choice of BTK inhibitor is guided by the setting (frontline vs relapsed) in conjunction with patient disease characteristics and comorbidities. In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy.
KW - CLL
KW - acalabrutinib
KW - atrial fibrillation
KW - bleeding
KW - hypertension
KW - ibrutinib
KW - zanubrutinib
UR - http://www.scopus.com/inward/record.url?scp=85130262524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130262524&partnerID=8YFLogxK
U2 - 10.1080/17474086.2022.2074393
DO - 10.1080/17474086.2022.2074393
M3 - Review article
C2 - 35507054
AN - SCOPUS:85130262524
SN - 1747-4086
VL - 15
SP - 403
EP - 409
JO - Expert review of hematology
JF - Expert review of hematology
IS - 5
ER -